Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 13/20 | 0.48 |
| ▸ | TDO2 | P48775 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3802980 | 0.94 | TDO2 (0.52) | GRM2TDO2KDM4ENPC1L3MBTL1 | |
| SCHEMBL9896568 | 0.82 | GRM2 (0.48) | GRM2TDO2 | |
| SCHEMBL9896854 | 0.77 | GRM2 (0.43) | GRM2TDO2NPC1L3MBTL1ALDH1A1 | |
| SCHEMBL9604234 | 0.76 | TDO2 (0.52) | GRM2TDO2ALDH1A1 | |
| SCHEMBL8510253 | 0.76 | TDO2 (0.52) | GRM2TDO2 | |
| SCHEMBL13240370 | 0.75 | GRM2 (0.60) | GRM2TDO2KDM4ENPC1ALDH1A1 | |
| SCHEMBL19848723 | 0.75 | CYP2D6 (0.48) | TDO2KDM4ENPC1L3MBTL1ALDH1A1 | |
| SCHEMBL19911594 | 0.74 | KDM4E (0.50) | GRM2KDM4ENPC1L3MBTL1MAPT | |
| SCHEMBL19911586 | 0.74 | HCAR3 (0.58) | KDM4ENPC1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL3475681 | 0.73 | GRM2 (0.57) | GRM2TDO2NPC1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975286-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975286-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975286-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2015-03-10 | — | — | US | disclosed |
| EP-2470527-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149677-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
| US-20120149677-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
| US-20120149677-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149677-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | GRM2, GRIA2, GRIK2 | GRM2 1/4885TDO2 1671/4885KDM4E 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.